{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274220","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.644303+00:00","generated_at":"2026-05-16T22:22:19.651392+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026","bullets":["Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.","R&D expenses $49.7M, up from $30.1M, driven by Phase 3 ARCHER II trial and global GBS regulatory filings.","Cash and equivalents $188.7M as of Sep 30, 2025; operations funded into late Q1 2027 through key milestones.","Tanruprubart (ANX005) GBS MAA submission on track for Jan 2026; FDA discussions on BLA generalizability package ongoing.","Vonaprument (ANX007) Phase 3 ARCHER II trial enrolled 659 GA patients; topline data expected second half 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274220","json":"https://secwatch.observer/filing/0001193125-25-274220.json","markdown":"https://secwatch.observer/filing/0001193125-25-274220.md","text":"https://secwatch.observer/filing/0001193125-25-274220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/0001193125-25-274220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/annx-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:22:19.651392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}